199 related articles for article (PubMed ID: 36792081)
21. PDE3A is hypermethylated in cisplatin resistant non-small cell lung cancer cells and is a modulator of chemotherapy response.
Tian FM; Zhong CY; Wang XN; Meng Y
Eur Rev Med Pharmacol Sci; 2017 Jun; 21(11):2635-2641. PubMed ID: 28678321
[TBL] [Abstract][Full Text] [Related]
22. MiR-219a-5p enhances cisplatin sensitivity of human non-small cell lung cancer by targeting FGF9.
Rao C; Miao X; Zhao G; Zhang C; Shen H; Dong C; Yang M
Biomed Pharmacother; 2019 Jun; 114():108662. PubMed ID: 30999114
[TBL] [Abstract][Full Text] [Related]
23. MiR-124 changes the sensitivity of lung cancer cells to cisplatin through targeting STAT3.
Qi MM; Ge F; Chen XJ; Tang C; Ma J
Eur Rev Med Pharmacol Sci; 2019 Jun; 23(12):5242-5250. PubMed ID: 31298375
[TBL] [Abstract][Full Text] [Related]
24. The regulatory and predictive functions of miR-17 and miR-92 families on cisplatin resistance of non-small cell lung cancer.
Zhao J; Fu W; Liao H; Dai L; Jiang Z; Pan Y; Huang H; Mo Y; Li S; Yang G; Yin J
BMC Cancer; 2015 Oct; 15():731. PubMed ID: 26482648
[TBL] [Abstract][Full Text] [Related]
25. MiR-192/NKRF axis confers lung cancer cell chemoresistance to cisplatin via the NF-κB pathway.
Li Y; Zu L; Wu H; Zhang F; Fan Y; Pan H; Du X; Guo F; Zhou Q
Thorac Cancer; 2022 Feb; 13(3):430-441. PubMed ID: 34953057
[TBL] [Abstract][Full Text] [Related]
26. Hypermethylation of mismatch repair gene hMSH2 associates with platinum-resistant disease in epithelial ovarian cancer.
Tian H; Yan L; Xiao-Fei L; Hai-Yan S; Juan C; Shan K
Clin Epigenetics; 2019 Oct; 11(1):153. PubMed ID: 31666131
[TBL] [Abstract][Full Text] [Related]
27. Pathogenesis and therapeutic strategy in platinum resistance lung cancer.
Lv P; Man S; Xie L; Ma L; Gao W
Biochim Biophys Acta Rev Cancer; 2021 Aug; 1876(1):188577. PubMed ID: 34098035
[TBL] [Abstract][Full Text] [Related]
28. CNOT3 contributes to cisplatin resistance in lung cancer through inhibiting RIPK3 expression.
Jing L; Zhai ME; Cui J; Fan XY; Cheng YY; Jiang JL; Chen ZN
Apoptosis; 2019 Aug; 24(7-8):673-685. PubMed ID: 31177396
[TBL] [Abstract][Full Text] [Related]
29. FAM60A promotes cisplatin resistance in lung cancer cells by activating SKP2 expression.
Hou Q; Jiang Z; Li Y; Wu H; Yu J; Jiang M
Anticancer Drugs; 2020 Sep; 31(8):776-784. PubMed ID: 32796403
[TBL] [Abstract][Full Text] [Related]
30. Global DNA methylation analysis reveals miR-214-3p contributes to cisplatin resistance in pediatric intracranial nongerminomatous malignant germ cell tumors.
Hsieh TH; Liu YR; Chang TY; Liang ML; Chen HH; Wang HW; Yen Y; Wong TT
Neuro Oncol; 2018 Mar; 20(4):519-530. PubMed ID: 29036598
[TBL] [Abstract][Full Text] [Related]
31. Mutant p53 confers chemoresistance in non-small cell lung cancer by upregulating Nrf2.
Tung MC; Lin PL; Wang YC; He TY; Lee MC; Yeh SD; Chen CY; Lee H
Oncotarget; 2015 Dec; 6(39):41692-705. PubMed ID: 26497680
[TBL] [Abstract][Full Text] [Related]
32. miR-206 regulates cisplatin resistance and EMT in human lung adenocarcinoma cells partly by targeting MET.
Chen QY; Jiao DM; Wang J; Hu H; Tang X; Chen J; Mou H; Lu W
Oncotarget; 2016 Apr; 7(17):24510-26. PubMed ID: 27014910
[TBL] [Abstract][Full Text] [Related]
33. miR-148b reverses cisplatin-resistance in non-small cell cancer cells via negatively regulating DNA (cytosine-5)-methyltransferase 1(DNMT1) expression.
Sui C; Meng F; Li Y; Jiang Y
J Transl Med; 2015 Apr; 13():132. PubMed ID: 25927928
[TBL] [Abstract][Full Text] [Related]
34. Mechanisms of resistance of human small cell lung cancer lines selected in VP-16 and cisplatin.
Jain N; Lam YM; Pym J; Campling BG
Cancer; 1996 May; 77(9):1797-808. PubMed ID: 8646677
[TBL] [Abstract][Full Text] [Related]
35. Krüppel-Like Factor 4 Enhances Sensitivity of Cisplatin to Lung Cancer Cells and Inhibits Regulating Epithelial-to-Mesenchymal Transition.
Liu S; Yang H; Chen Y; He B; Chen Q
Oncol Res; 2016; 24(2):81-7. PubMed ID: 27296948
[TBL] [Abstract][Full Text] [Related]
36. Epigenetic silencing of miR-493 increases the resistance to cisplatin in lung cancer by targeting tongue cancer resistance-related protein 1(TCRP1).
Gu Y; Zhang Z; Yin J; Ye J; Song Y; Liu H; Xiong Y; Lu M; Zheng G; He Z
J Exp Clin Cancer Res; 2017 Aug; 36(1):114. PubMed ID: 28859669
[TBL] [Abstract][Full Text] [Related]
37. Expression of xeroderma pigmentosum complementation group C protein predicts cisplatin resistance in lung adenocarcinoma patients.
Lai TC; Chow KC; Fang HY; Cho HC; Chen CY; Lin TY; Chiang IP; Ho SP
Oncol Rep; 2011 May; 25(5):1243-51. PubMed ID: 21327329
[TBL] [Abstract][Full Text] [Related]
38. Differential methylation EPIC analysis discloses cisplatin-resistance related hypermethylation and tumor-specific heterogeneity within matched primary and metastatic testicular germ cell tumor patient tissue samples.
Lobo J; Constâncio V; Leite-Silva P; Guimarães R; Cantante M; Braga I; Maurício J; Looijenga LHJ; Henrique R; Jerónimo C
Clin Epigenetics; 2021 Apr; 13(1):70. PubMed ID: 33823933
[TBL] [Abstract][Full Text] [Related]
39. GAS5 knockdown reduces the chemo-sensitivity of non-small cell lung cancer (NSCLC) cell to cisplatin (DDP) through regulating miR-21/PTEN axis.
Cao L; Chen J; Ou B; Liu C; Zou Y; Chen Q
Biomed Pharmacother; 2017 Sep; 93():570-579. PubMed ID: 28686971
[TBL] [Abstract][Full Text] [Related]
40. Different mechanisms of cisplatin resistance development in human lung cancer cells.
Okamoto K; Saito Y; Narumi K; Furugen A; Iseki K; Kobayashi M
Biochem Biophys Res Commun; 2020 Oct; 530(4):745-750. PubMed ID: 32782152
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
